| ■ 영문 제목 : Advanced Therapy Medicinal Products CDMO Market Size, Share & Trends Analysis Report By Product (Gene Therapy, Cell Therapy, Tissue Engineered), By Phase, By Indication, By Region, And Segment Forecasts, 2023 - 2030
|
 | ■ 상품코드 : GRV23MA018
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 1월
■ 페이지수 : 157
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 의료
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1인 열람용) | USD5,950 ⇒환산￦8,330,000 | 견적의뢰/주문/질문 |
| Multi User (5인 열람용) | USD6,950 ⇒환산￦9,730,000 | 견적의뢰/주문/질문 |
| Global/corporate License (기업 열람용) | USD8,950 ⇒환산￦12,530,000 | 견적의뢰/구입/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
미국 Grand View Research (그랜드뷰리서치)는 세계의 첨단 치료제 CDMO 시장 규모가 2023년부터 2030년 사이에 연평균 18.8% 성장하여, 2030년에는 188억 달러에 달할 것으로 예측하고 있습니다. 본 조사 자료는 세계의 첨단 치료제 CDMO 시장을 조사대상으로 하여, 조사 방법 및 범위, 개요, 시장 변동/동향/범위, 제품별 (유전자 치료, 세포 요법, 조직 공학) 분석, 단계별 (1단계, 2단계, 3단계, 4단계) 분석, 질환별 (종양, 순환기, 중추 신경계, 근골격계, 기타) 분석, 지역별 (북미, 유럽, 아시아 태평양, 중남미, 중동/아프리카) 분석, 경쟁 현황 등의 내용을 게재하고 있습니다. 또한 본 자료는 CELONIC Group, Bio Elpida, Rentschler Biopharma SE, AGC Biologics, Catalent, Inc., Lonza, WuXi Advanced Therapies, Minaris Regenerative Medicine, Patheon, Inc., Cell and Gene Therapy Catapult (CGT Catapult) 와 같은 기업 정보를 포함하고 있습니다.
・조사 방법 및 범위
・개요
・시장 변동/동향/범위
・세계의 첨단 치료제 CDMO 시장 규모 : 제품별
- 유전자 치료제 CDMO의 시장 규모
- 세포 요법 CDMO의 시장 규모
- 조직 공학 CDMO의 시장 규모
- 기타 제품의 시장 규모
・세계의 첨단 치료제 CDMO 시장 규모 : 단계별
- 1단계 첨단 치료제 CDMO의 시장 규모
- 2단계 첨단 치료제 CDMO의 시장 규모
- 3단계 첨단 치료제 CDMO의 시장 규모
- 4단계 첨단 치료제 CDMO의 시장 규모
・세계의 첨단 치료제 CDMO 시장 규모 : 질환별
- 종양에 사용되는 CDMO의 시장 규모
- 순환기에 사용되는 CDMO의 시장 규모
- 중추 신경계에 사용되는 CDMO의 시장 규모
- 근골격계에 사용되는 CDMO의 시장 규모
- 기타 질환에 사용되는 CDMO의 시장 규모
・세계의 첨단 치료제 CDMO 시장 규모 : 지역별
- 북미의 첨단 치료제 CDMO 시장 규모
- 유럽의 첨단 치료제 CDMO 시장 규모
- 아시아 태평양의 첨단 치료제 CDMO 시장 규모
- 중남미의 첨단 치료제 CDMO 시장 규모
- 중동/아프리카의 첨단 치료제 CDMO 시장 규모
・경쟁 현황
・기업 정보 |
■ 보고서 개요Advanced Therapy Medicinal Products CDMO Market Growth & Trends
The global advanced therapy medicinal products CDMO market size is expected to reach USD 18.8 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 18.8% from 2023 to 2030, owing to rising clinical trials for advanced therapy medicinal products and the increasing awareness among researchers about the benefits of advanced therapies, driving the advanced therapy medicinal products (ATMP) CDMO market growth. Tissue engineering has greatly benefited in recent years from technological development. The damaged tissues and organ function are replaced or restored using this technique. Similarly, gene and cell therapy are attracting a lot of patients for the treatment of rare diseases, whose incidence is rising globally.
With rising demand for robust disease treatment therapies, key players have focused their efforts to ramp up research and development for effective gene therapies that target the cause of disorder at a genomic level. According to ASGCT, the number of cell and gene therapies in the U.S. pipeline programs (phase I-III trials) increased from 483 in 2021 to 529 in 2022. Furthermore, the FDA delivers constant support for innovations in the gene therapy field via a number of policies with regard to product manufacturing. In January 2020, the agency released six final guidelines on the manufacturing and clinical development of safe & efficient gene therapy products.
Moreover, awareness about ATMP treatment options is being driven by initiatives aimed at informing the public about the benefits of these products, which, in turn, is leading to increased adoption of advanced therapies and fueling market growth for CDMOs. For instance, Alliance for Regenerative Medicine Foundation for Cell and Gene Medicine prioritizes activities for increasing public awareness through educational programs, underlining the clinical & societal benefits of regenerative medicine.
Increasing clinical trial activity along with new product launches generates growth opportunities for the market. As of 2022, there are 1451 ATMPs in preclinical stages and 535 are being studied in Phase 1 to 3 studies. Since August 2020, EMA has approved six of these additional ATMPs, and five more will be approved by 2023. In the UK, there were approximately 168 advanced therapy medicinal product trials underway in 2021, up from the 154 studies reported the year before, which is a 9% increase. 2021 saw a 32% increase in phase 1 trials, indicating a significant shift from experimental medicines to first-in-human studies.
On the other hand, key players are undertaking various strategic initiatives to introduce novel products, which is expected to propel market growth. For instance, in March 2021, CureVac N.V. signed a partnership agreement with Celonic Group, engaged in the manufacture of CVnCoV, CureVac’s mRNA-based COVID-19 vaccine candidate. CureVac’s COVID-19 vaccine candidate is manufactured at Celonic’s commercial manufacturing unit for ATMPs and biologics in Heidelberg, Germany. Under the terms of the commercial supply agreement, the Celonic facility could produce over 100 million doses of CVnCoV.
Advanced Therapy Medicinal Products CDMO Market Report Highlights
• By product, gene therapy accounted for a major share of market space due to increasing clinical trials for gene therapies. Moreover, collaborative efforts for the development of novel gene therapies and the resultant expansion in gene therapy applications are factors expected to drive the volume of manufacturing
• Cell therapy is expected to account for a significant market share in the coming years. A rise in research interests and the adoption of advanced cell therapies are attracting increased investments. The segment is being driven by CDMOs attracting investments to keep up with growing commercial markets and support their growth and diversification prospects
• By phase, the phase I segment dominated the market revenue share in 2022. This is attributed to the growing number of human trials for advanced therapies and rising R&D activities
• By indication, the oncology segment held a major share of the market in 2022 due to the increasing number of cancer patients and increasing cell and gene therapy research related to cancer. Moreover, technological advancements, such as the development of cancer vaccines, are expected to further support segment growth
• North America dominated the global market in 2022, owing to increasing healthcare expenditure and the presence of key players. Companies such as Novartis AG, Sanofi, Johnson & Johnson Services, Inc., and Viatris are positively influencing market growth
• For instance, in June 2022, Novartis AG launched Dimethyl fumarate HEXAL for the treatment of patients with Relapsing-Remitting Multiple Sclerosis (RRMS) in Germany. This strategic launch was aimed at commercializing Hexal in Germany
• The Asia Pacific region is expected to expand considerably in the future. China is one of the major markets in the region. The market growth can be attributed to increasing government investments and reforms in policies related to the manufacturing of pharmaceutical products. China ranked second in the world for cell & gene therapy development with more than 1,000 clinical trials conducted in the country
■ 보고서 목차Table of Contents
Chapter 1 Methodology and Scope
1.1 Market Segmentation & Scope
1.1.1 Regional Scope
1.1.2 Estimates and forecast timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased database:
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.1.1 Approach 1: Commodity Flow Approach
1.7 List of Secondary Sources
1.8 Objectives
1.8.1 Objective 1
1.8.2 Objective 2
1.8.3 Objective 3
1.8.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Advanced Therapy Medicinal Products CDMO Market Variables, Trends, and Scope
3.1 Market Dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Rising number of clinical trials for ATMPs
3.1.1.2 Increasing outsourcing activities
3.1.1.3 Growing awareness of the treatment
3.1.2 Market Restraint Analysis
3.1.2.1 Stringent regulatory approvals
3.1.2.2 High cost of outsourcing
3.2 Business Environment Analysis Tools
3.2.1 SWOT Analysis; By factor (Political & Legal, Economic and Technological)
3.2.2 Porter’s Five Forces Analysis
Chapter 4 Advanced Therapy Medicinal Products CDMO Market – Segment Analysis, By Product, 2018 – 2030 (USD Billion)
4.1 Advanced Therapy Medicinal Products CDMO market: Product Movement Analysis
4.2 Gene Therapy
4.2.1 Gene therapy market estimates and forecast, 2018 – 2030 (USD Billion)
4.3 Cell Therapy
4.3.1 Cell therapy market estimates and forecast, 2018 – 2030 (USD Billion)
4.4 Tissue Engineered
4.4.1 Tissue engineered market estimates and forecast, 2018 – 2030 (USD Billion)
4.5 Others
4.5.1 Others market estimates and forecast, 2018 – 2030 (USD Billion)
Chapter 5 Advanced Therapy Medicinal Products CDMO Market – Segment Analysis, By Phase, 2018 – 2030 (USD Billion)
5.1 Advanced Therapy Medicinal Products CDMO market: Phase movement analysis
5.2 Phase 1
5.2.1 Phase 1 market estimates and forecast, 2018 – 2030 (USD Billion)
5.3 Phase 2
5.3.1 Phase 2 market estimates and forecast, 2018 – 2030 (USD Billion)
5.4 Phase 3
5.4.1 Phase 3 market estimates and forecast, 2018 – 2030 (USD Billion)
5.5 Phase 4
5.5.1 Phase 4 market estimates and forecast, 2018 – 2030 (USD Billion)
Chapter 6 Advanced Therapy Medicinal Products CDMO Market – Segment Analysis, By Indication, 2018 – 2030 (USD Billion)
6.1 Advanced therapy medicinal products CDMO market: Indication movement analysis
6.2 Oncology
6.2.1 Oncology market estimates and forecast, 2018 – 2030 (USD Billion)
6.3 Cardiology
6.3.1 Cardiology market estimates and forecast, 2018 – 2030 (USD Billion)
6.4 Central Nervous System
6.4.1 Central nervous system market estimates and forecast, 2018 – 2030 (USD Billion)
6.5 Musculoskeletal
6.5.1 Musculoskeletal market estimates and forecast, 2018 – 2030 (USD Billion)
6.6 Infectious Disease
6.6.1 Infectious disease market estimates and forecast, 2018 – 2030 (USD Billion)
6.7 Dermatology
6.7.1 Dermatology market estimates and forecast, 2018 – 2030 (USD Billion)
6.8 Endocrine, Metabolic, Genetic
6.8.1 Endocrine, metabolic, genetic market estimates and forecast, 2018 – 2030 (USD Billion)
6.9 Immunology & Inflammation
6.9.1 Immunology & inflammation market estimates and forecast, 2018 – 2030 (USD Billion)
6.10 Ophthalmology
6.10.1 Ophthalmology market estimates and forecast, 2018 – 2030 (USD Billion)
6.11 Hematology
6.11.1 Hematology market estimates and forecast, 2018 – 2030 (USD Billion)
6.12 Gastroenterology
6.12.1 Gastroenterology market estimates and forecast, 2018 – 2030 (USD Billion)
6.13 Others
6.13.1 Others market estimates and forecast, 2018 – 2030 (USD Billion)
Chapter 7 Advanced Therapy Medicinal Products CDMO Market: Regional Market Analysis, 2018 – 2030 (USD Billion)
7.1 North America
7.1.1 SWOT Analysis
7.1.1.1 North America Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.1.2 U.S.
7.1.2.1 Key Country Dynamics
7.1.2.2 Target Disease Prevalence
7.1.2.3 Competitive Scenario
7.1.2.4 Regulatory Framework
7.1.2.5 Reimbursement Scenario
7.1.2.6 U.S. Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.1.3 Canada
7.1.3.1 Key Country Dynamics
7.1.3.2 Target Disease Prevalence
7.1.3.3 Competitive Scenario
7.1.3.4 Regulatory Framework
7.1.3.5 Reimbursement Scenario
7.1.3.6 Canada Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2 Europe
7.2.1 SWOT Analysis:
7.2.1.1 Europe Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.2 Germany
7.2.2.1 Key Country Dynamics
7.2.2.2 Target Disease Prevalence
7.2.2.3 Competitive Scenario
7.2.2.4 Regulatory Framework
7.2.2.5 Reimbursement Scenario
7.2.2.6 Germany Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.3 UK
7.2.3.1 Key Country Dynamics
7.2.3.2 Target Disease Prevalence
7.2.3.3 Competitive Scenario
7.2.3.4 Regulatory Framework
7.2.3.5 Reimbursement Scenario
7.2.3.6 UK Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.4 France
7.2.4.1 Key Country Dynamics
7.2.4.2 Target Disease Prevalence
7.2.4.3 Competitive Scenario
7.2.4.4 Regulatory Framework
7.2.4.5 Reimbursement Scenario
7.2.4.6 France Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.5 Italy
7.2.5.1 Key Country Dynamics
7.2.5.2 Target Disease Prevalence
7.2.5.3 Competitive Scenario
7.2.5.4 Regulatory Framework
7.2.5.5 Reimbursement Scenario
7.2.5.6 Italy Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.6 Spain
7.2.6.1 Key Country Dynamics
7.2.6.2 Target Disease Prevalence
7.2.6.3 Competitive Scenario
7.2.6.4 Regulatory Framework
7.2.6.5 Reimbursement Scenario
7.2.6.6 Spain Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.7 Denmark
7.2.7.1 Key Country Dynamics
7.2.7.2 Target Disease Prevalence
7.2.7.3 Competitive Scenario
7.2.7.4 Regulatory Framework
7.2.7.5 Reimbursement Scenario
7.2.7.6 Denmark Advanced therapy Medicinal products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.8 Sweden
7.2.8.1 Key Country Dynamics
7.2.8.2 Target Disease Prevalence
7.2.8.3 Competitive Scenario
7.2.8.4 Regulatory Framework
7.2.8.5 Reimbursement Scenario
7.2.8.6 Sweden Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.9 Norway
7.2.9.1 Key Country Dynamics
7.2.9.2 Target Disease Prevalence
7.2.9.3 Competitive Scenario
7.2.9.4 Regulatory Framework
7.2.9.5 Reimbursement Scenario
7.2.9.6 Norway Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.2.10 Rest of Europe Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3 Asia Pacific
7.3.1 SWOT Analysis:
7.3.1.1 Key Region Dynamics
7.3.1.2 Asia Pacific Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.2 Japan
7.3.2.1 Target Disease Prevalence
7.3.2.2 Competitive Scenario
7.3.2.3 Regulatory Framework
7.3.2.4 Reimbursement Scenario
7.3.2.5 Japan Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.3 China
7.3.3.1 Target Disease Prevalence
7.3.3.2 Competitive Scenario
7.3.3.3 Regulatory Framework
7.3.3.4 Reimbursement Scenario
7.3.3.5 China Advanced Therapy Medicinal Prodcut CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.4 India
7.3.4.1 Target Disease Prevalence
7.3.4.2 Competitive Scenario
7.3.4.3 Regulatory Framework
7.3.4.4 Reimbursement Scenario
7.3.4.5 India Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.5 South Korea
7.3.5.1 Target Disease Prevalence
7.3.5.2 Competitive Scenario
7.3.5.3 Regulatory Framework
7.3.5.4 Reimbursement Scenario
7.3.5.5 South Korea Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.6 Australia
7.3.6.1 Target Disease Prevalence
7.3.6.2 Competitive Scenario
7.3.6.3 Regulatory Framework
7.3.6.4 Reimbursement Scenario
7.3.6.5 Austrlia Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.7 Thailand
7.3.7.1 Target Disease Prevalence
7.3.7.2 Competitive Scenario
7.3.7.3 Regulatory Framework
7.3.7.4 Reimbursement Scenario
7.3.7.5 Thailand Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.3.8 Rest of Asia Pacific Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4 Latin America
7.4.1 SWOT Analysis:
7.4.2 KEY Regional DYNAMICS
7.4.2.1 Latin America Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4.3 Brazil
7.4.3.1 Target Disease Prevalence
7.4.3.2 Competitive Scenario
7.4.3.3 Regulatory Framework
7.4.3.4 Reimbursement Scenario
7.4.3.5 Brazil Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4.4 Mexico
7.4.4.1 Target Disease Prevalence
7.4.4.2 Competitive Scenario
7.4.4.3 Regulatory Framework
7.4.4.4 Reimbursement Scenario
7.4.4.5 Mexico Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4.5 Argentina
7.4.5.1 Target Disease Prevalence
7.4.5.2 Competitive Scenario
7.4.5.3 Regulatory Framework
7.4.5.4 Reimbursement Scenario
7.4.5.5 Argentina Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4.6 Colombia
7.4.6.1 Target Disease Prevalence
7.4.6.2 Competitive Scenario
7.4.6.3 Regulatory Framework
7.4.6.4 Reimbursement Scenario
7.4.6.5 Colombia Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4.7 Chile
7.4.7.1 Target Disease Prevalence
7.4.7.2 Competitive Scenario
7.4.7.3 Regulatory Framework
7.4.7.4 Reimbursement Scenario
7.4.7.5 Chile Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.4.8 Rest of LATAM Advanced therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5 Middle East & Africa (MEA)
7.5.1 SWOT Analysis:
7.5.2 KEY regional DYNAMICS
7.5.2.1 Middle East & Africa advanced therapy medicinal products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.3 South Africa
7.5.3.1 Target Disease Prevalence
7.5.3.2 Competitive Scenario
7.5.3.3 Regulatory Framework
7.5.3.4 Reimbursement Scenario
7.5.3.5 Brazil Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.4 Saudi Arabia
7.5.4.1 Target Disease Prevalence
7.5.4.2 Competitive Scenario
7.5.4.3 Regulatory Framework
7.5.4.4 Reimbursement Scenario
7.5.4.5 Saudi Arabia Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.5 UAE
7.5.5.1 Target Disease Prevalence
7.5.5.2 Competitive Scenario
7.5.5.3 Regulatory Framework
7.5.5.4 Reimbursement Scenario
7.5.5.5 UAE Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.6 Israel
7.5.6.1 Target Disease Prevalence
7.5.6.2 Competitive Scenario
7.5.6.3 Regulatory Framework
7.5.6.4 Reimbursement Scenario
7.5.6.5 Israel Advanced Therapy Medicinal product CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.7 Egypt
7.5.7.1 Target Disease Prevalence
7.5.7.2 Competitive Scenario
7.5.7.3 Regulatory Framework
7.5.7.4 Reimbursement Scenario
7.5.7.5 Egypt Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.8 Kuwait
7.5.8.1 Target Disease Prevalence
7.5.8.2 Competitive Scenario
7.5.8.3 Regulatory Framework
7.5.8.4 Reimbursement Scenario
7.5.8.5 Kuwait Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
7.5.9 Rest of MEA Advanced Therapy Medicinal Products CDMO Market Estimates and Forecasts, 2018 – 2030 (USD Billion)
Chapter 8 Advanced Therapy Medicinal Products CDMO Market: Competitive Analysis
8.1 Strategic Framework
8.2 Company Profiles
8.2.1 CELONIC Group
8.2.1.1 Company Overview
8.2.1.2 Product Benchmarking
8.2.1.3 Strategic Initiatives
8.2.2 Bio Elpida
8.2.2.1 Company Overview
8.2.2.2 Product Benchmarking
8.2.2.3 Strategic Initiatives
8.2.3 Rentschler Biopharma SE
8.2.3.1 Company Overview
8.2.3.2 Product Benchmarking
8.2.3.3 Strategic Initiatives
8.2.4 AGC Biologics
8.2.4.1 Company Overview
8.2.4.2 Product Benchmarking
8.2.4.3 Strategic Initiatives
8.2.5 Catalent, Inc.
8.2.5.1 Company Overview
8.2.5.2 Financial Performance
8.2.5.3 Product Benchmarking
8.2.5.4 Strategic Initiatives
8.2.6 Lonza
8.2.6.1 Company Overview
8.2.6.2 Financial Performance
8.2.6.3 Product Benchmarking
8.2.6.4 Strategic Initiatives
8.2.7 WuXi Advanced Therapies
8.2.7.1 Company Overview
8.2.7.2 Product Benchmarking
8.2.7.3 Strategic Initiatives
8.2.8 Minaris Regenerative Medicine
8.2.8.1 Company Overview
8.2.8.2 Product Benchmarking
8.2.8.3 Strategic Initiatives
8.2.9 Patheon, Inc.
8.2.9.1 Company Overview
8.2.9.2 Financial Performance
8.2.9.3 Product Benchmarking
8.2.9.4 Strategic Initiatives
8.2.10 Cell and Gene Therapy Catapult (CGT Catapult)
8.2.10.1 Company Overview
8.2.10.2 Financial Performance
8.2.10.3 Product Benchmarking
8.2.10.4 Strategic Initiatives
|
| ※본 조사보고서 [세계의 첨단 치료제 CDMO 시장 (2023-2030) : 유전자 치료, 세포 요법, 조직 공학] (코드 : GRV23MA018) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 첨단 치료제 CDMO 시장 (2023-2030) : 유전자 치료, 세포 요법, 조직 공학] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요! 세계의 첨단 치료제 CDMO 시장 (2023-2030) : 유전자 치료, 세포 요법, 조직…
